



**HAL**  
open science

# Computed and subjective blue scleral color analysis as a diagnostic tool for iron deficiency

Hervé Lobbes

► **To cite this version:**

Hervé Lobbes. Computed and subjective blue scleral color analysis as a diagnostic tool for iron deficiency. Human health and pathology. 2019. dumas-02460610

**HAL Id: dumas-02460610**

**<https://dumas.ccsd.cnrs.fr/dumas-02460610v1>**

Submitted on 30 Jan 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



UNIVERSITÉ CLERMONT AUVERGNE  
UFR DE MÉDECINE ET DES PROFESSIONS PARAMÉDICALES

THÈSE D'EXERCICE  
pour le  
DIPLOME D'ÉTAT DE DOCTEUR EN MÉDECINE  
par

LOBBES, Hervé, Bertrand, Antoine

Présentée et soutenue publiquement le 4 juillet 2019

Computed and subjective blue scleral color analysis as a diagnostic tool for iron deficiency.

Directeur de thèse : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Président du jury : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Membres du jury : Monsieur TOURNILHAC Olivier, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Monsieur ANDRE Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Madame VAILLANT-ROUSSEL Hélène, Maître de Conférence, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.





UNIVERSITÉ CLERMONT AUVERGNE  
UFR DE MÉDECINE ET DES PROFESSIONS PARAMÉDICALES

THÈSE D'EXERCICE  
pour le  
DIPLOME D'ÉTAT DE DOCTEUR EN MÉDECINE  
par

LOBBES, Hervé, Bertrand, Antoine

Présentée et soutenue publiquement le 4 juillet 2019

Computed and subjective blue scleral color analysis as a diagnostic tool for iron deficiency.

Directeur de thèse : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Président du jury : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Membres du jury : Monsieur TOURNILHAC Olivier, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Monsieur ANDRE Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

Madame VAILLANT-ROUSSEL Hélène, Maître de Conférence, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand.

## UNIVERSITE CLERMONT AUVERGNE

---

PRESIDENTS HONORAIRES  
UNIVERSITE D'AUVERGNE

: **JOYON** Louis  
: **DOLY** Michel  
: **TURPIN** Dominique  
: **VEYRE** Annie  
: **DULBECCO** Philippe  
: **ESCHALIER** Alain

PRESIDENTS HONORAIRES  
UNIVERSITE BLAISE PASCAL

: **CABANES** Pierre  
: **FONTAINE** Jacques  
: **BOUTIN** Christian  
: **MONTEIL** Jean-Marc  
: **ODOUARD** Albert  
: **LAVIGNOTTE** Nadine

PRESIDENT DE L'UNIVERSITE et  
PRESIDENT DU CONSEIL ACADEMIQUE PLENIER  
PRESIDENT DU CONSEIL ACADEMIQUE RESTREINT  
VICE-PRESIDENT DU CONSEIL D'ADMINISTRATION  
VICE-PRESIDENT DE LA COMMISSION DE LA RECHERCHE  
VICE PRESIDENTE DE LA COMMISSION DE LA  
FORMATION ET DE LA VIE UNIVERSITAIRE  
DIRECTEUR GENERAL DES SERVICES

: **BERNARD** Mathias  
: **DEQUIEDT** Vianney  
: **WILLIAMS** Benjamin  
: **HENRARD** Pierre  
  
: **PEYRARD** Françoise  
: **PAQUIS** François



## UFR DE MEDECINE ET DES PROFESSIONS PARAMEDICALES

DOYENS HONORAIRES

: **DETEIX** Patrice  
: **HAZAL** Jean

DOYEN  
RESPONSABLE ADMINISTRATIVE

: **CLAVELOU** Pierre  
: **ROBERT** Gaëlle

## LISTE DU PERSONNEL ENSEIGNANT

### PROFESSEURS HONORAIRES :

MM. BACIN Franck - BEGUE René-Jean - BOUCHER Daniel - BOURGES Michel - BUSSIÈRE Jean-Louis - CANO Noël - CASSAGNES Jean - CATILINA Pierre - CHABANNES Jacques - CHAZAL Jean - CHIPPONI Jacques - CHOLLET Philippe - COUDERT Jean - DASTUGUE Bernard - DEMEOCQ François - DE RIBEROLLES Charles - ESCANDE Georges - Mme FONCK Yvette - MM. GENTOU Claude - GLANDDIER Gérard - Mmes GLANDDIER Phyllis - LAVARENNE Jeanine - MM. LAVERAN Henri - LEVAI Jean-Paul - MAGE Gérard - MALPUECH Georges - MARCHEIX Jean-Claude - MICHEL Jean-Luc - MOLINA Claude - MONDIE Jean-Michel - PERI Georges - PETIT Georges - PHILIPPE Pierre - PLAGNE Robert - PLANCHE Roger - PONSONNAILLE Jean - RAYNAUD Elie - REY Michel - Mme RIGAL Danièle - MM. ROZAN Raymond - SCHOEFFLER Pierre - SIROT Jacques - SOUTEYRAND Pierre - TANGUY Alain - TERVER Sylvain - THIEBLOT Philippe - TOURNILHAC Michel - VANNEUVILLE Guy - VIALLET Jean-François - Mle VEYRE Annie

### PROFESSEURS EMERITES :

MM. - BEYTOUT Jean - BOITEUX Jean-Paul - BOMMELAER Gilles - CHAMOIX Alain - DAUPLAT Jacques - DETEIX Patrice - ESCHALIER Alain - IRTHUM Bernard - JACQUETIN Bernard - KEMENY Jean-Louis - Mme LAFEUILLE Hélène - MM. LEMERY Didier - LESOURD Bruno - LUSSON Jean-René - RIBAL Jean-Pierre

## PROFESSEURS DES UNIVERSITES-PRATICIENS HOSPITALIERS

### *PROFESSEURS DE CLASSE EXCEPTIONNELLE*

M.	VAGO Philippe	Histologie-Embryologie Cytogénétique
M.	AUMAITRE Olivier	Médecine Interne
M.	LABBE André	Pédiatrie
M.	AVAN Paul	Biophysique et Traitement de l'Image
M.	DURIF Franck	Neurologie
M.	BOIRE Jean-Yves	Biostatistiques, Informatique Médicale et Technologies de Communication
M.	BOYER Louis	Radiologie et Imagerie Médicale option Clinique
M.	POULY Jean-Luc	Gynécologie et Obstétrique
M.	CANIS Michel	Gynécologie-Obstétrique
Mme	PENAULT-LLORCA Frédérique	Anatomie et Cytologie Pathologiques
M.	BAZIN Jean-Etienne	Anesthésiologie et Réanimation Chirurgicale
M.	BIGNON Yves Jean	Cancérologie option Biologique
M.	BOIRIE Yves	Nutrition Humaine
M.	CLAVELOU Pierre	Neurologie
M.	DUBRAY Claude	Pharmacologie Clinique
M.	GILAIN Laurent	O.R.L.

M.	LEMAIRE Jean-Jacques	Neurochirurgie
M.	CAMILLERI Lionel	Chirurgie Thoracique et Cardio-Vasculaire
M.	DAPOIGNY Michel	Gastro-Entérologie
M.	LLORCA Pierre-Michel	Psychiatrie d'Adultes
M.	PEZET Denis	Chirurgie Digestive
M.	SOUWEINE Bertrand	Réanimation Médicale
M.	BOISGARD Stéphane	Chirurgie Orthopédique et Traumatologie
M.	CONSTANTIN Jean-Michel	Anesthésiologie et Réanimation Chirurgicale
Mme	DUCLOS Martine	Physiologie
M.	SCHMIDT Jeannot	Thérapeutique

**PROFESSEURS DE**  
**1ère CLASSE**

M.	DECHELOTTE Pierre	Anatomie et Cytologie Pathologique
M.	CAILLAUD Denis	Pneumo-physiologie
M.	VERRELLE Pierre	Radiothérapie option Clinique
M.	CITRON Bernard	Cardiologie et Maladies Vasculaires
M.	D'INCAN Michel	Dermatologie -Vénérologie
Mme	JALENQUES Isabelle	Psychiatrie d'Adultes
Mlle	BARTHELEMY Isabelle	Chirurgie Maxillo-Faciale
M.	GARCIER Jean-Marc	Anatomie-Radiologie et Imagerie Médicale
M.	GERBAUD Laurent	Epidémiologie, Economie de la Santé et Prévention
M.	SOUBRIER Martin	Rhumatologie
M.	TAUVERON Igor	Endocrinologie et Maladies Métaboliques
M.	MOM Thierry	Oto-Rhino-Laryngologie
M.	RICHARD Ruddy	Physiologie
M.	RUIVARD Marc	Médecine Interne
M.	SAPIN Vincent	Biochimie et Biologie Moléculaire
M.	BAY Jacques-Olivier	Cancérologie
M.	BERGER Marc	Hématologie
M.	COUDEYRE Emmanuel	Médecine Physique et de Réadaptation
Mme	GODFRAIND Catherine	Anatomie et Cytologie Pathologiques
M.	ROSSET Eugénio	Chirurgie Vasculaire
M.	ABERGEL Armando	Hépatologie
M.	LAURICHESSE Henri	Maladies Infectieuses et Tropicales
M.	TOURNILHAC Olivier	Hématologie
M.	CHIAMBARETTA Frédéric	Ophthalmologie
M.	FILAIRE Marc	Anatomie – Chirurgie Thoracique et Cardio-Vasculaire
M.	GALLOT Denis	Gynécologie-Obstétrique
M.	GUY Laurent	Urologie
M.	TRAORE Ousmane	Hygiène Hospitalière
M.	ANDRE Marc	Médecine Interne
M.	BONNET Richard	Bactériologie, Virologie
M.	CACHIN Florent	Biophysique et Médecine Nucléaire
M.	COSTES Frédéric	Physiologie
M.	FUTIER Emmanuel	Anesthésiologie-Réanimation
Mme	HENG Anne-Elisabeth	Néphrologie
M.	MOTREFF Pascal	Cardiologie
Mme	PICKERING Gisèle	Pharmacologie Clinique

**PROFESSEURS DE  
2<sup>ème</sup> CLASSE**

Mme CREVEAUX Isabelle	Biochimie et Biologie Moléculaire
M. FAICT Thierry	Médecine Légale et Droit de la Santé
Mme KANOLD LASTAWIECKA Justyna	Pédiatrie
M. TCHIRKOV Andréi	Cytologie et Histologie
M. CORNELIS François	Génétique
M. DESCAMPS Stéphane	Chirurgie Orthopédique et Traumatologique
M. POMEL Christophe	Cancérologie – Chirurgie Générale
M. CANAVESE Fédérico	Chirurgie Infantile
M. LESENS Olivier	Maladies Infectieuses et Tropicales
M. RABISCHONG Benoît	Gynécologie Obstétrique
M. AUTHIER Nicolas	Pharmacologie Médicale
M. BROUSSE Georges	Psychiatrie Adultes/Addictologie
M. BUC Emmanuel	Chirurgie Digestive
M. CHABROT Pascal	Radiologie et Imagerie Médicale
M. LAUTRETTE Alexandre	Néphrologie Réanimation Médicale
M. AZARNOUSH Kasra	Chirurgie Thoracique et Cardiovasculaire
Mme BRUGNON Florence	Biologie et Médecine du Développement et de la Reproduction
Mme HENQUELL Cécile	Bactériologie Virologie
M. ESCHALIER Romain	Cardiologie
M. MERLIN Etienne	Pédiatrie
Mme TOURNADRE Anne	Rhumatologie
M. DURANDO Xavier	Cancérologie
M. DUTHEIL Frédéric	Médecine et Santé au Travail
Mme FANTINI Maria Livia	Neurologie
M. SAKKA Laurent	Anatomie – Neurochirurgie
M. BOURDEL Nicolas	Gynécologie-Obstétrique
M. GUIEZE Romain	Hématologie
M. POINCLOUX Laurent	Gastroentérologie
M. SOUTEYRAND Géraud	Cardiologie

**PROFESSEURS DES UNIVERSITES**

M. CLEMENT Gilles	Médecine Générale
Mme MALPUECH-BRUGERE Corinne	Nutrition Humaine
M. VORILHON Philippe	Médecine Générale

**PROFESSEURS ASSOCIES DES UNIVERSITES**

Mme BOTTET-MAULOUBIER Anne	Médecine Générale
M. CAMBON Benoît	Médecine Générale



## MAITRES DE CONFERENCES DES UNIVERSITES - PRATICIENS HOSPITALIERS

### *MAITRES DE CONFERENCES HORS CLASSE*

Mme CHAMBON Martine	Bactériologie Virologie
Mme BOUTELOUP Corinne	Nutrition

### *MAITRES DE CONFERENCES DE 1ère CLASSE*

M. MORVAN Daniel	Biophysique et Traitement de l'Image
Mlle GOUMY Carole	Cytologie et Histologie, Cytogénétique
Mme FOGLI Anne	Biochimie Biologie Moléculaire
Mlle GOUAS Laetitia	Cytologie et Histologie, Cytogénétique
M. MARCEAU Geoffroy	Biochimie Biologie Moléculaire
Mme MINET-QUINARD Régine	Biochimie Biologie Moléculaire
M. ROBIN Frédéric	Bactériologie
Mlle VERONESE Lauren	Cytologie et Histologie, Cytogénétique
M. DELMAS Julien	Bactériologie
Mlle MIRAND Andrey	Bactériologie Virologie
M. OUCHCHANE Lemlih	Biostatistiques, Informatique Médicale et Technologies de Communication
M. LIBERT Frédéric	Pharmacologie Médicale
Mlle COSTE Karen	Pédiatrie
M. EVRARD Bertrand	Immunologie
Mlle AUMERAN Claire	Hygiène Hospitalière
M. POIRIER Philippe	Parasitologie et Mycologie
Mme CASSAGNES Lucie	Radiologie et Imagerie Médicale
M. LEBRETON Aurélien	Hématologie

### *MAITRES DE CONFERENCES DE 2ème CLASSE*

Mme PONS Hanaë	Biologie et Médecine du Développement et de la Reproduction
M. JABAUDON-GANDET Matthieu	Anesthésiologie – Réanimation Chirurgicale
M. BOUVIER Damien	Biochimie et Biologie Moléculaire
M. BUISSON Anthony	Gastroentérologie
M. COLL Guillaume	Neurochirurgie
Mme SARRET Catherine	Pédiatrie
M. MAQDASY Salwan	Endocrinologie, Diabète et Maladies Métaboliques
Mme NOURRISSON Céline	Parasitologie - Mycologie

## MAITRES DE CONFERENCES DES UNIVERSITES

Mme BONHOMME Brigitte	Biophysique et Traitement de l'Image
Mme VAURS-BARRIERE Catherine	Biochimie Biologie Moléculaire
M. BAILLY Jean-Luc	Bactériologie Virologie
Mlle AUBEL Corinne	Oncologie Moléculaire
M. BLANCHON Loïc	Biochimie Biologie Moléculaire
Mlle GUILLET Christelle	Nutrition Humaine
M. BIDEY Yannick	Oncogénétique
M. MARCHAND Fabien	Pharmacologie Médicale
M. DALMASSO Guillaume	Bactériologie
M. SOLER Cédric	Biochimie Biologie Moléculaire
M. GIRAUDET Fabrice	Biophysique et Traitement de l'Image
Mme VAILLANT-ROUSSEL Hélène	Médecine Générale
Mme LAPORTE Catherine	Médecine Générale
M. LOLIGNIER Stéphane	Neurosciences – Neuropharmacologie
Mme MARTEIL Gaëlle	Biologie de la Reproduction
M. PINEL Alexandre	Nutrition Humaine

## MAITRES DE CONFERENCES ASSOCIES DES UNIVERSITES

M. TANGUY Gilles	Médecine Générale
M. BERNARD Pierre	Médecine Générale
Mme ESCHALIER Bénédicte	Médecine Générale
Mme RICHARD Amélie	Médecine Générale

## **Dédicaces aux membres du jury :**

**Au président du jury**, monsieur le professeur **Marc RUIVARD** : vous m'avez très tôt accordé votre confiance pour mener de nombreux projets. Votre bienveillance tout au long de ceux-ci est un honneur. Votre exigence médicale, intellectuelle et humaine est une grande source d'inspiration pour moi. Je vous remercie d'avoir dirigé ce travail et de prendre la présidence du jury chargé de le juger.

### **Aux membres du jury :**

Au Professeur Olivier **TOURNILHAC** : votre présence au sein du jury chargé d'évaluer ma thèse m'honore. J'ai eu la chance de profiter de votre enseignement lors de mon passage dans votre service et espère avoir le plaisir de continuer à collaborer avec vous.

Au Professeur Marc **ANDRE** : votre présence dans mon jury de thèse est un honneur. Vous m'avez transmis votre rigueur scientifique et la soif d'excellence de notre discipline. Je vous remercie d'avoir ainsi accepté de juger mon travail.

Au Professeur Hélène **VAILLANT-ROUSSEL** : je vous remercie d'avoir accepté de participer au jury de ma thèse. Votre présence m'honore et signe toute l'importance des liens entre nos disciplines.

## **Remerciements :**

Je tiens à remercier avec beaucoup de chaleur le Professeur Laurent Sarry et le Dr Julien Dehos, sans qui ce travail n'aurait pas pu voir le jour. Votre contribution est majeure depuis la conception technique de l'application jusqu'à l'analyse informatisée des images. Les améliorations successives ont permis d'obtenir des résultats prometteurs. Cette collaboration a été très enrichissante et je vous en suis très reconnaissant.

Je remercie également les stagiaires de Master Bio-informatique qui ont successivement participé à l'élaboration du code OpenCV et au développement de l'application mobile sous la direction du Professeur Sarry et du Dr Dehos : Claire Berthommier, Olfa Graa, Coralie Rodrigues et Jérémy Mezhoud.

## **Dédicaces personnelles :**

A toi, Camille, ma tendre épouse qui m'encourage chaque jour et m'apporte tant de bonheur. A tes côtés je m'épanouis en tant que médecin, mais surtout en tant qu'homme, et bientôt en tant que père. Comme le dit un poète : les mots manquent aux émotions.

Je t'aime.

A toi, ma fille.

Nous t'attendons le cœur débordant de joie.

A mon père et à ma mère, pour leur soutien sans faille, pour leur aide logistique qui m'a permis de passer les écueils de la 1<sup>o</sup> année (et de toutes les suivantes !). Pour leur écoute, leurs encouragements toujours renouvelés. Pour l'exemple qu'ils sont pour moi au quotidien. Et pour tout l'amour qu'ils m'ont offert. A mon frère et à Manon, pour leur bienveillance, leur écoute patiente et passionnée, et pour tous nos partages autour de notre métier de soignant.

Votre regard m'emplit de fierté.

A mes tantes et oncles qui ont suivi avec enthousiasme mon parcours, m'ont encouragé et aidé par leur écoute et leurs conseils. A Pascale, qui m'a apporté tant de lumière les 6 mois à Paris.

Un immense merci.

A toute ma belle-famille, dont l'attention et l'affection pour moi n'a cessé de croître d'années en années. A Jean, dont l'engagement sans faille auprès des patients et l'humilité dans l'exercice de notre métier seront toujours pour moi des modèles. A Fabi, pour ses précieux conseils pour améliorer la communication médecin-patient, et son intégrité professionnelle.

Je vous remercie du fond du cœur.

A mes amis et amies, rencontrés à Dax, à Bordeaux, à Moulins, à Clermont. Pour leurs encouragements toujours renouvelés, les repas et les bouffées d'air frais : Ludovic, Alexandre, Arnaud, Flora et Thomas, Amandine et Benjamin, Olivia et Thomas, Florianne et Guillaume.

Vous m'êtes infiniment précieux.

Aux médecins que j'ai eu la chance de côtoyer durant mon internat, qui m'ont transmis leurs connaissances, leur rigueur de travail, leur passion et leur humanité. En particulier le Dr Cyril Garrouste, les Dr Virginie Rieu, Guillaume Le Guenno et Vincent Grobost, le Pr Alexandre Lautrette et le Dr Christophe Leroy, le Dr Perrine Smets, les Prs Tournadre et Soubrier, les Prs Godeau et Michel et le Dr Mahévas.

Vous m'avez accueilli dans vos services et fait de moi le médecin que je suis aujourd'hui. J'espère me montrer digne de votre enseignement.

A Bruno Pereira pour son aide si précieuse, sa capacité d'adaptation et de compréhension, sa patience et ses explications sans lesquelles rien n'aurait été possible.

A tous mes co-internes, qui sont souvent devenus des amis précieux et en particulier : Clémence, Benjamin R, Julie, Marion, Lucie, Cyril C, Benjamin C, Mélissa, Julien.

Aux équipes d'infirmières et d'aides-soignantes, aux assistantes sociales et aux secrétaires médicales, précieuses collègues de travail, qui m'ont accompagné, aidé, soutenu, avec qui j'ai ri et pleuré -parfois, et tant appris.

Merci pour ces années ensemble si enrichissantes.

## Table des matières

1. Introduction: .....	13
2. Patients and methods: .....	15
2.1 Ethics.....	15
2.2 Patients .....	15
2.2 Analysis of eye image .....	16
2.3 Outcome assessment .....	17
2.4 Statistical analysis .....	18
3. Results: .....	19
3.1 Inclusion characteristics .....	20
3.2 Physician assessment of blue sclera color.....	21
3.3 Computed analysis of blue color.....	23
3.4 ROC curves for computed blue color .....	24
4. Discussion: .....	26
Conclusion :.....	29
Références bibliographiques : .....	30
Annexes :.....	33

## Liste des tableaux et figures :

### TABLEAUX

Table I	Baseline characteristics of the population	20
Table II	Subjective assessment of blue sclera and iron stores by physician	21
Table III	Subjective assessment of blue sclera and iron stores (3 physicians together)	22
Table IV	Computed blue color assessment in ID and NID subjects	23
Table V	MS computed blue color by physician.	23

### FIGURES

Figure 1	Flowchart	19
Figure 2	ROC curves for computed blue color	24-25

## **Liste des abréviations :**

BMI: Body Mass Index

BP: Blue Percentile

CPP: Comité de Protection des personnes.

CRP: C-reactive protein.

HGA: Homogentisic Acid.

ID: Iron deficiency.

IQR: Inter-Quartile Range.

LR: Likelihood Ratio.

NPV: Negative Predictive Value.

OI: Osteogenesis Imperfecta.

PPV: Positive Predictive Value.

ROC: Receiver operating characteristic.

SF: Serum Ferritin.

TPS: Transferrin Percent Saturation.

WHO: World Health Organization.

## 1. Introduction:

Iron deficiency (ID) is the world's most common form of nutritional deficiency (1), with a prevalence ranging from 4.5% to 18% in most recent studies in the US (2). ID remains the most common cause of anemia (3), with an annual incidence of 7.2-13.96 per 1000 person-years in Europe (4). ID leads to disability through impairment of cognitive function (5), functional capacity and quality of life (6,7), and it can be improved by iron supplementation. Consequently, ID is a major issue for practitioners in primary care.

ID diagnosis is based on serum ferritin level which is the most specific and sensitive test (8,9) with a cut-off  $\leq 30 \mu\text{g/L}$  or  $\leq 100 \mu\text{g/L}$  in cases of ID accompanied by inflammation. Clinical findings depend on the depth and speed of onset of the anemia. Most findings are common to all types of anemia (mucosal pallor, fatigue, headache and tachycardia) (10) but some manifestations are deemed to be specific to ID. Indeed, iron is involved in multiple functions of epithelial cells, which are characterized by their high turn-over. As such, various mucocutaneous manifestations are reported to be caused by ID such as skin dryness and roughness, mild alopecia, atrophic glossitis or koilonychia (11).

Among these signs, blueish coloration of the sclera was first described in 1908 by Osler in iron-deficient malnourished teenagers. Since then, sporadic reports have been published, indicating the diagnostic potential interest of blue sclera in ID (12). In the late 1980s, Kalra et al (13,14) published two studies claiming that blue sclera was a highly sensitive and specific sign of ID. These findings were later confirmed by Clemente et al (15) and Kotsev et al (16). In both studies, assessment of the blueish coloration of the sclera relied on subjective appreciation by independent physicians, who were asked to grade the color as absent, equivocal, definite or striking. Blue sclera can be associated with other conditions such as collagen diseases, for example in osteogenesis imperfecta, but these conditions are less common than ID.



Despite these encouraging results, the use of blue sclera has only rarely been reported and its assessment could be a simple diagnostic tool for ID in primary care. Therefore, we aimed to determine the real value of the blueish tint in the sclera for the diagnosis of ID, through subjective and computed analyses of eye images obtained using a smartphone.

## 2. Patients and methods:

### *2.1 Ethics*

We conducted a pragmatic prospective monocentric study in Clermont-Ferrand University Hospital. In line with French regulations, ethical approval was obtained from the International Review Board “CPP Sud EST VI”, reference number 2019/CE02. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Recommendations.

### *2.2 Patients*

The inclusion criteria were: patients aged  $\geq 18$ -years, with:

- Suspicion of ID:
  - clinical suspicion supported for example by pruritus, fatigue, pallor, tachycardia, restless leg syndrome, glossitis.
  - biological suspicion defined by microcytic hypochromic anemia with low reticulocyte count.
- Biological assessment of serum iron stores by at least one of the following biological analyses: serum ferritin (SF) or Transferrin Percent Saturation (TPS).

Exclusion criteria were medical history of Marfan or Ehler Danlos syndrome, scurvy or osteogenesis imperfecta, or eye surgery or injury.

## *2.2 Analysis of eye image*

A preliminary two-step study was conducted using the first nine patients to enroll (17). First, a smartphone application was created using OpenCV library to provide a repeatable image acquisition using multiple time exposure. We decided to use a smartphone device (Google Nexus 5X®) instead of a powerful professional camera because the aim was to allow widespread use of this diagnostic tool. The smartphone application allowed us to anonymize the pictures and to collect clinical and biological data for each patient. Automated color correction and automatic white balance of the camera were disabled. To measure the “true” color of a picture, we used a white reference provided by a color-checker (X-rite®), which placed by the physician next to the eye, to take a picture including both the eye and white patch of the color-checker. Second, post-processing software was created to analyze the blue color of the sclera. To obtain High Dynamic Range pictures, images with multiple time exposures were merged into a single image. Finally, the software analyzed the percentage of each color (red, green and blue) in scleral pixels after white correction.

The pictures were taken by the same physician throughout the study. Exposure conditions were standardized: the patient sat next to a window, in natural daylight. There was no direct contact with the patient, so the process was completely non-invasive.

Three independent physicians who were blinded to the presence or absence of ID subjectively assessed the blueish coloration of the sclera in anonymized pictures. The sequence of evaluation was randomized for each physician. Blue color was evaluated as: 1 (absent), 2 (equivocal), 3 (definite) and 4 (striking).

Clinical data (age, sex, height, weight, Body-Mass-Index = BMI) and biological data were collected at the same time. Iris color was graded as light (grey, green, blue) or dark.

### *2.3 Outcome assessment*

ID was defined as stated by Camaschella and colleagues (18) by one of the following criteria:

- SF  $\leq$  30  $\mu\text{g/L}$  or  $\leq$  100  $\mu\text{g/L}$  in case of inflammatory syndrome (elevation of C-reactive protein).
- TPS  $\leq$  16% and SF  $\leq$  300  $\mu\text{g/L}$ .

Subjective blue color of the sclera was defined by a sign graded as definite or striking. We also used the definition used in previous studies in that at least two physicians had to state that the sign as definite or striking (13–16).

Objective blue color was measured by computer analysis as the percentage of blue color in the 25% most blue pixel in the area of interest, which can be interpreted as a Blue Percentile (BP) in the analyzed pixels.

We used three methods to delineate the area of interest of the sclera:

- Automated method: the sclera is automatically recognized by the software and the whole sclera is analyzed. This method is termed Full-Sclera (FS).
- Semi-automated method: the physician selects the bluest area of the sclera to allow the software to delineate a small area of pixels with the same color characteristics. This method is termed Semi-Automated Sclera (SAS).
- Manual method: the analyzed area of sclera is manually delimited by the physician who delineates the bluest area of the sclera. This method is termed Manual Sclera (MS).

## 2.4 Statistical analysis


Because we conducted an exploratory study, no calculation of power or number of subjects could be made. All statistical analyses performed using Stata version 13 (StataCorp, College Station, TX, USA), for a two-sided type I error at 5%. The categorical parameters were expressed as numbers and percentages, whereas the quantitative variables were described as mean  $\pm$  standard deviation or median with [interquartile range], according to the statistical distribution. Normality was studied using the Shapiro-Wilk test. The inter-rater reliability and agreement with the gold standard were evaluated using Lin's concordance coefficient for quantitative variables and Fleiss's  $\kappa$  coefficient for categorical data. The results were studied according to the usual rules defined in literature (19): 0.00-0.20 (poor agreement), 0.21-0.40 (fair agreement), 0.41-0.60 (moderate agreement), 0.61-0.80 (good agreement) and  $> 0.80$  (very good agreement). Then, the between-group comparisons (ID vs. no ID: NID) were performed using the following statistical tests: Student's  $t$ -test or Mann-Whitney test if the assumptions of the  $t$ -test were not met (normality, and homoscedasticity as identified by the Fisher-Snedecor test) for quantitative variables and  $\chi^2$  test or if necessary, Fisher's exact test for categorical variables. Statistical analyses were completed by analyzing the Receiver Operating Characteristic (ROC) curve to determine the most appropriate threshold to predict ID, for each method: FS, SAS and MS. The optimal threshold was determined according to usual indexes reported in medical literature (Youden, Liu and efficiency). Then, sensitivity, specificity and predictive values were estimated and expressed with 95% confidence interval.

### 3. Results:

From November 2014 to July 2018, 83 consecutive inpatients were enrolled in the study. As previously stated, we adjusted the technical settings on the camera to provide adequate picture quality using the first nine patients to enroll.

During the second phase, we tested 74 patients using the same procedure for shooting and the same camera settings. We excluded seven patients: four were excluded because of poor picture quality (blurred images, over- or underexposed images) and three because of a lack of data regarding iron stores. A total of 67 patients were included in the final analysis.

**Figure 1:** flowchart.



### 3.1 Inclusion characteristics

Baseline characteristics are shown in **Table I**. Male:female ratio was 0.8 in the overall population and was significantly lower in the ID group (0.59) than in the NID group (2.2). Mean age was significantly higher in the ID group ( $p = 0.01$ ). Overall, 52/67 (77.6%) patients had anemia (hemoglobin  $\leq 12$  g/dL for women,  $\leq 13$  g/dL for men): 46/51 in the ID group and 6/16 in the NID group.

**Table I:** Baseline characteristics of the population.

	All (n = 67)	ID (n = 51)	NID (n = 16)
Male (%)	30 (44%)	19 (37%)	11 (68%)
Mean age (yr)	59.9 $\pm$ 20.1	63.1 $\pm$ 20.3	49.6 $\pm$ 16.4
BMI (kg/m <sup>2</sup> )	26.2 $\pm$ 7.3	26.7 $\pm$ 7.8	24.5 $\pm$ 5.6
Dark iris, n (%)	43 (64%)	35 (68%)	8 (50%)
Hemoglobin (g/dL)	10.3 $\pm$ 2.5	9.7 $\pm$ 2.1	12 $\pm$ 3
No. of patients with anemia (male)	52 (22)	46 (19)	6 (3)
Mean corpuscular volume (fL)	84.4 $\pm$ 8.5	82.4 $\pm$ 7.8	90.5 $\pm$ 8
Platelet count (G/L)	255 $\pm$ 116	267 $\pm$ 113	217 $\pm$ 119
Ferritin ( $\mu$ g/L)	28.5 [16;75]	20.5 [11;34]	244.5 [111.7;440.7]
TPS (%)	9.6 [6;38.5]	8 [6;11]	40 [32.5;54]
Fibrinogen (g/L)	4.2 $\pm$ 1.8	4.2 $\pm$ 1.6	4.2 $\pm$ 2.8
C-reactive protein (g/L)	9.6 [2.9;37.5]	13.5 [3.5;43]	2.9 [2.9;9]

Data are expressed as mean  $\pm$  standard deviation or as median [interquartile range].

### 3.2 Physician assessment of blue sclera color

We first compared physician assessments of sclera color and iron stores (ID or NID) (Table II). Blue color of the sclera was defined for each physician by a sign graded as definite or striking.

**Table II:** Subjective assessment of blue sclera and iron stores by physician.

		NID (n = 16)	ID (n = 51)
Physician 1	Blue (%)	5 (31.25)	31 (60.78)
	No blue (%)	11 (68.75)	20 (39.22)
Physician 2	Blue (%)	3 (18.75)	23 (45.09)
	No blue (%)	13 (81.25)	28 (54.91)
Physician 3	Blue (%)	1 (6.25)	15 (29.41)
	No blue (%)	15 (93.75)	36 (70.59)

We found a significant association between subjective blue color assessment of the sclera by physician 1 and the diagnosis of ID ( $p = 0.03$ ,  $\chi^2 = 4.27$ ), whereas there was a non-significant trend for physicians 2 ( $p = 0.05$ ,  $\chi^2 = 3.56$ ) and 3 ( $p = 0.05$  by Fisher's exact test due to the small sample size). Subjective analysis of blue color was not influenced for any of the physicians by iris color ( $p = 0.28$ ,  $p = 0.37$  and  $p = 0.44$  respectively), sex ( $p = 0.58$ ,  $p = 0.23$ ,  $p = 0.50$ ) or by the presence of anemia ( $p = 0.22$ ,  $p = 0.08$ ,  $p = 0.07$ , respectively).



Sensitivity was low: 60.8% [CI95: 46.1;74.2%] for physician 1, 45.1% [CI95: 31.1;59.7%] for physician 2 and 29.4% [CI95: 17.5;43.8%] for physician 3. Specificity was 68.8% [CI95: 41.3;89%] for physician 1, 81.3% [CI95: 54.4;96%] for physician 2 and 93.8% [CI95: 69.8;99.8%] for physician 3. Positive predictive value (PPV) was 86.1% [CI95: 70.5;95.3], 88.5% [CI95: 69.8;97.6%] and 93.8% [CI95: 69.8;99.8] for physicians 1, 2 and 3 respectively. Negative predictive value (NPV) was low: 35.5% [CI95: 19.2;54.6%], 31.7% [CI95: 18.1;48.1%] and 29.4% [CI95: 17.5;43.8%] for physicians 1, 2 and 3, respectively. Positive likelihood ratio (LR) was 1.95 [CI95: 0.91;4.16], 2.41 [CI95: 0.83;6.97] and 4.71 [CI95: 0.67;32.9] for physicians 1, 2 and 3, respectively.

When we used the definition of blue sclera found in previous studies (**Table III**), we found no significant association between blue sclera and ID ( $p = 0.09$ ). This result could be linked to a poor inter-rater reliability, as shown by the Fleiss's  $\kappa$  value which was between 0.09 and 0.23. Sensitivity was 51% [CI95: 36.6;56.2%], specificity was 93.8% [CI95: 69.8;99.8%], PPV was 96.3% [CI95: 81;99.9%] and NPV 37.5% [CI95: 22.7;54.2%]. Positive LR was 8.16 [CI95: 1.2;55.5].

**Table III:** Subjective assessment of blue sclera and iron stores (3 physicians together).

	NID (n = 16)	ID (n = 51)
Blue (%)	1 (6.25)	26 (50.98)
No-blue (%)	15 (93.75)	25 (49.02)

### 3.3 Computed analysis of blue color

The correlation between the three methods of computed sclera color analysis was excellent, as shown by the Pearson correlation test:  $r = 0.929$  (FS vs. MS),  $r = 0.927$  (FS vs SAS) and  $r = 0.945$  (MS vs. SAS). We found no effect of iris color on computed results of sclera color analysis via any of the three methods (FS:  $p = 0.68$ ; MS:  $p = 0.88$ ; SAS:  $p = 0.94$ )

Computed results of blue color analysis are shown in **Table IV**. Blue color seemed to be higher in ID than in NID subjects for all three methods, but the difference reached significance only for the MS method ( $p = 0.04$ , FS method:  $p = 0.12$  and SAS method:  $p = 0.05$ ).

**Table IV:** Computed blue color assessment in ID and NID subjects. Results are presented as mean  $\pm$  SD blue percentile (BP).

	NID (n = 16)	ID (n = 51)
FS (BP)	29.18 $\pm$ 4.31	31.07 $\pm$ 3.33
MS (BP)	29.12 $\pm$ 3.53	31.24 $\pm$ 3.39
SAS (BP)	29.03 $\pm$ 3.87	31.19 $\pm$ 3.29

For physicians 1 and 3, the MS-computed blue color was significantly higher in patients with blue sclera (graded as definite or striking) compared to patients without blue sclera ( $p = 0.002$  and  $p < 0.001$  respectively, **Table V**). For physician 2, the difference did not reach statistical significance ( $p = 0.33$ ).

**Table V:** MS computed blue color by physician. Results are presented as mean  $\pm$  SD blue percentile.


	Physician 1	Physician 2	Physician 3
No blue	29.27 $\pm$ 4.19	30.42 $\pm$ 3.93	30.01 $\pm$ 3.93
Blue	32 $\pm$ 2.17	31.23 $\pm$ 2.75	33.03 $\pm$ 1.93

### 3.4 ROC curves for computed blue color


For the detection of ID, the ROC curve with the FS method (Figure 2A) showed a sensitivity of 90.2% [CI95: 78.6;96.7%], a specificity of 43.8% [CI95: 19.8;70.1%], PPV of 83.6% [CI95: 71.2;92.2%] and NPV of 58.3% [CI95: 27.7;84.8%] with a threshold of 27.6 (Youden index). The MS method (Figure 2B) showed a sensitivity of 78.4% [CI95: 64.7;88.7%], a specificity of 50% [CI95: 24.7;75.3%], PPV of 83.3% [CI95: 69.8;92.5%] and NPV of 42.1% [CI95: 20.3;66.5%] with a threshold of 29.1 and the highest area-under-the-curve of 0.7 [CI95: 0.54;0.85]. The SAS method (Figure 2C) showed a sensitivity of 84.3% [CI95: 71.4;93%], a specificity of 50% [CI95: 24.7;75.3%], PPV of 84.3% [CI95: 71.4;93%] and NPV of 50% [CI95: 24.7;75.3%] with a threshold of 28.9.

**Figure 2:** ROC curves for computed blue color.


**2A:** FS method.



**2B: MS method.**



**2C: SAS method.**



## 4. Discussion:

To our best knowledge, ours is the first attempt to provide an objective measurement of blue sclera as a diagnostic tool for ID. We proceeded to a two-step study. First, we evaluated subjective blue color assessment by three well-trained physicians who were blinded to the results of iron-store analysis. Our results are at odds with previously published work (13). In our study, PPV was high (86.1-93.8% depending on the physician) but sensitivity and specificity were low. One explanation could be the difference in inclusion criteria. We included patients based on clinical or biological suspicion of ID, while previous studies included patients with and without suspicion of anemia or ID. Furthermore, assessment of blue color was different in our study, to ensure blindness of the physicians: color assessment was undertaken on anonymized pictures in our study while it was live in previous studies. Second, we applied a computer analysis of blue scleral color. Noticeably, the blue color was higher in patients graded with blue sclera by physicians and in ID. Results were contradictory depending on the methodology used to delineate the sclera. The best results were obtained with the MS method, but specificity was poor with the three methods.

Blue coloration of the sclera can be found in a wide variety of conditions. For example, antibiotic treatment by minocycline is known to induce blue pigmentation of teeth, ears and sclera (20) which is also found in alkaptonuria, a rare autosomal-recessive disorder leading to an accumulation of homogentisic acid (HGA) in connective tissues which induces blueish coloration (21). None of our patients had a history of prolonged minocycline therapy or of symptoms consistent with alkaptonuria (osteoarthritis and dark urine). We did not measure HGA in urine, therefore diagnosis of alkaptonuria cannot be ruled out in our patients although the rarity of this disease makes this hypothesis highly unlikely (22). Other rare inherited conditions with connective tissue abnormalities can also be associated with blueish discoloration of the sclera, such as: Ehlers-Danlos syndrome (23), Marshall-Smith syndrome

(24), Loeys-Dietz syndrome (25), De Barsy syndrome (26) or Mevalonic Aciduria (27). The best-known and most frequent alternate diagnosis of blue sclera due to genetic disorder is osteogenesis imperfecta (OI) (28): mutations in *COL1A1* or *COL1A2* genes lead to quantitative or qualitative defects in type 1 collagen inducing bone fragility. Notably, none of our patients had a history of multiple bone fractures or dysmorphic features.

Electron microscopy of sclera tissues from OI patients revealed reduced collagen thickness of collagen fibers indicative of immature collagen, which is more translucent than normal collagen. This feature could explain the blueish coloration by making the blood vessels and underlying uveal pigment more visible (29,30). To the best of our knowledge, such a study in ID patients has not been conducted but the same hypothesis can be proposed to explain the blue coloration in our patients. Collagen structure of the sclera is composed of 90% type I collagen fibers (31) whose synthesis requires non-heme iron prolyl-4-hydroxylase (32). We postulate that ID leads to impaired synthesis of type I collagen fibers reducing sclera thickness and resulting in blueish coloration. This hypothesis could be easily verified through non-invasive measurement of the sclera by anterior-segment optical coherent tomography (33).

Blue coloration of the sclera in our study was assessed in a similar way to previous studies of this feature in ID patients (13–16). In OI, blue coloration was graded by comparison of commercial scale of blue color. The grades ranged from 8 (bluest grade) which was a 50% dilution of the hue of a 4 year-old patient suffering with OI, to 1 (almost white) by 50% dilution between each grade (34). In our study, physicians graded the blue color in comparison with an absolute white color provided by a color-checker (X-Rite®), but the inter-rater reliability was poor. Any attempt to increase the complexity of the grading might reduce even furthermore the extent of agreement between the assessors. Interestingly, iris color affected neither the assessment of the physician nor the computed analysis of the sclera color.

Finally, the small size of our population meant that we could not performed an analysis according to ethnicity. Furthermore, we could not evaluate the impact of the severity of ID nor its duration. Further studies should focus on improvement of blue detection to enhance specificity. Improvement of this innovative method could provide a simple diagnostic tool for ID for physicians involved in primary care.

## Conclusion :

Physician assessment of blue sclera has a good PPV for the diagnosis of ID in subjects with clinical or biological suspicion of ID. However, sensitivity and specificity are poor, and the inter-rater agreement is low. Interestingly, iris color affected neither the assessment of the physician nor the computed analysis of the sclera color. Computed analysis provides encouraging results: blue color was higher in ID than in NID, but the diagnostic value depended on the methodology used to delineate the sclera. Further studies should focus on the improvement of blue detection to enhance specificity. The improvement of this innovative method could provide an easy handling diagnosis tool of great interest for primary care physician in ID diagnosis.

La valeur prédictive positive de la couleur bleue de la sclère est élevée pour le diagnostic de carence martiale chez des sujets présentant des signes cliniques ou biologiques évocateurs. Cependant, la sensibilité et la spécificité sont faibles tout comme le niveau d'accord inter-observateur. De façon intéressante, la couleur de l'iris n'influe pas sur l'évaluation subjective ou informatisée de la couleur de la sclère. Les résultats obtenus par analyse informatique de la couleur de la sclère sont encourageants : un taux de bleu plus élevé est retrouvé chez les sujets présentant une carence martiale mais la valeur diagnostique de cette mesure dépend de la méthode de délimitation de la sclère. Augmenter la détection de la quantité de bleue devrait permettre d'améliorer la spécificité de ce signe. L'amélioration de cette méthodologie innovante pourrait fournir à terme un outil intéressant chez les praticiens de premier recours pour le diagnostic de carence martiale.

Clermont-Ferrand, le  
Pierre CLAVELOU  
Doyen – Directeur

Clermont-Ferrand, le 17/05/19  
Marc RUIVARD  
Président du Jury

CHU de CLERMONT-FERRAND  
MEDECINE INTERNE - CHU ESTAING  
Professeur Marc RUIVARD  
N° A.D.E.L.L. : 63 10 4570 5  
N° RPPS : 10001275246  
Tél. : 04.73.750.085 - Fax : 04.73.750.361





## Références bibliographiques :

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutr.* 2009;12:444–54.
2. Mei Z, Cogswell ME, Looker AC, Pfeiffer CM, Cusick SE, Lacher DA, Grummer-Strawn LM. Assessment of iron status in US pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. *Am J Clin Nutr.* 2011;93:1312–20.
3. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, et al. A systematic analysis of global anemia burden from 1990 to 2010. *Blood.* 2014;123:615–24.
4. Levi M, Rosselli M, Simonetti M, Brignoli O, Cancian M, Masotti A, Pegoraro V, Cataldo N, Heiman F, Chelo M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. *Eur J Haematol.* 2016;97:583–93.
5. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. *Lancet.* 1996;348:992–6.
6. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med.* 2009;361:2436–48.
7. Krayenbuehl P-A, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. *Blood.* 2011;118:3222–7.
8. Daru J, Colman K, Stanworth SJ, De La Salle B, Wood EM, Pasricha S-R. Serum ferritin as an indicator of iron status: what do we need to know? *Am J Clin Nutr.* 2017;106:1634S-1639S.
9. Camaschella C. Iron deficiency. *Blood.* 2019;133:30–9.
10. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. *The Lancet.* 2016;387:907–16.
11. Sato S. Iron deficiency: structural and microchemical changes in hair, nails, and skin. *Semin Dermatol.* 1991;10:313–9.
12. Hall GH. New sign of iron deficiency? *Lancet.* 1971;2:935.
13. Kalra L, Hamlyn AN, Jones BJ. Blue sclerae: a common sign of iron deficiency? *Lancet.* 1986;2:1267–9.
14. Kalra L, Treloar A, Price R, Jones BJ. Blue sclerae and iron deficiency in general practice. *Lancet.* 1987;1:335.

15. Iglesias Clemente JM, Rodríguez García S, Molina Hernando MA. [Evaluation of a clinical sign in predicting iron deficiency in women: the blue sclera]. *Aten Primaria*. 1990;7:552–4.
16. Kotsev I, Pavlov S, Zheleva D, Gencheva T. [Blue sclera in iron deficiency conditions]. *Klin Med (Mosk)*. 1991;69:85–6.
17. Berthommier C. Development of a diagnosis tool based on color measurement of the eye [Unpublished Master Thesis]. Limoges University; 2016.
18. Camaschella C. New insights into iron deficiency and iron deficiency anemia. *Blood Rev*. 2017;31:225–33.
19. Altman DG. Practical statistics for medical research. *Statistics in Medicine*, Chapman and Hall. 1991;10:1635–6.
20. Johnston S. Feeling blue? Minocycline-induced staining of the teeth, oral mucosa, sclerae and ears – a case report. *British Dental Journal*. 2013;215:71–3.
21. Suwannarat P, Phornphutkul C, Bernardini I, Turner M, Gahl WA. Minocycline-induced hyperpigmentation masquerading as alkaptonuria in individuals with joint pain. *Arthritis & Rheumatism*. 2004;50:3698–701.
22. Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). *J Clin Pathol*. 2013;66:367–73.
23. Kosho T. CHST14/D4ST1 deficiency: New form of Ehlers–Danlos syndrome. *Pediatrics International*. 2016;58:88–99.
24. Adam MP, Hennekam RCM, Keppen LD, Bull MJ, Clericuzio CL, Burke LW, Ormond KE, Hoyme EH. Marshall–Smith syndrome: Natural history and evidence of an osteochondrodysplasia with connective tissue abnormalities. *American Journal of Medical Genetics Part A*. 2005;137A:117–24.
25. Drera B, Ritelli M, Zoppi N, Wischmeijer A, Gnoli M, Fattori R, Calzavara-Pinton PG, Barlati S, Colombi M. Loeys–Dietz syndrome type I and type II: clinical findings and novel mutations in two Italian patients. *Orphanet J Rare Dis*. 2009;4:24.
26. Kivuva EC, Parker MJ, Cohen MC, Wagner BE, Sobey G. De Barsy syndrome: a review of the phenotype. *Clinical Dysmorphology*. 2008;17:99.
27. Wilker SC, Dagnelie G, Goldberg MF. Retinitis Pigmentosa And Punctate Cataracts In Mevalonic Aciduria. *Retinal Cases & Brief Reports*. 2010;4:34–6.
28. Tournis S, Dede AD. Osteogenesis imperfecta - A clinical update. *Metab Clin Exp*. 2018;80:27–37.
29. Chan CC, Green WR, Cruz ZC de la, Hillis A. Ocular Findings in Osteogenesis Imperfecta Congenita. *Arch Ophthalmol*. 1982;100:1459–63.
30. Lanting PJH, Borsboom PCF, Meerman GJ te, Kate LP ten. Decreased scattering coefficient of blue sclerae. *Clinical Genetics*. 1985;27:187–90.


31. Coudrillier B, Pijanka J, Jefferys J, Sorensen T, Quigley HA, Boote C, Nguyen TD. Collagen Structure and Mechanical Properties of the Human Sclera: Analysis for the Effects of Age. *J Biomech Eng.* 2015;137:0410061–04100614.
32. Shoulders MD, Raines RT. COLLAGEN STRUCTURE AND STABILITY. *Annu Rev Biochem.* 2009;78:929–58.
33. Buckhurst HD, Gilmartin B, Cubbidge RP, Logan NS. Measurement of Scleral Thickness in Humans Using Anterior Segment Optical Coherent Tomography. *PLoS One* [Internet]. 2015 [cited 2019 Feb 4];10. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517791/>
34. Silience D, Butler B, Latham M, Barlow K. Natural history of blue sclerae in osteogenesis imperfecta. *American Journal of Medical Genetics.* 1993;45:183–6.

## Annexes :


**Annexe 1 :** Picture of eye and color-checker (X-Rite®) for physician assessment of blue sclera.




**Annexe 2:** Computed analysis of blue sclera (FS method).



### Annexe 3 : Computed analysis of blue sclera (SAS method).



**Annexe 4:** Computed analysis of blue sclera (MS method).



## **Serment d'Hippocrate :**

(conseil national de l'ordre des médecins)

Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.

Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.

Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte je ne ferai pas usage de mes connaissances contre les lois de l'humanité.

J'informerai les patients des décisions envisagées, des raisons et de leurs conséquences. Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences.

Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admis(e) dans l'intimité des personnes, je tairai les secrets qui me sont confiés. Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.

Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.

Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque.



## **Serment d'Hippocrate :**

En présence des MAÎTRES de cette faculté et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine.

Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail. Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les mœurs ni à favoriser le crime.

Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque.

## **Étude de la couleur bleue de la sclère pour le diagnostic de carence martiale : analyse clinique et informatisée.**

**Introduction :** la carence martiale (CM) est fréquente en soins primaires. Les signes cliniques sont pauvres : le diagnostic repose sur le dosage de la ferritine sérique. La présence d'une sclère bleue serait un signe sensible et spécifique de CM. Notre objectif était d'évaluer la valeur diagnostique de ce signe pour le diagnostic de CM.

**Méthodes :** une photographie par smartphone des yeux de 74 patients suspects de CM était réalisée de façon standardisée. Trois médecins indépendants évaluaient en aveugle la couleur de la sclère sur les images anonymisées. Une analyse informatisée déterminait le percentile de bleu dans les pixels de la sclère. La CM était définie par une ferritine  $\leq 30 \mu\text{g/L}$  ( $100 \mu\text{g/L}$  en cas de syndrome inflammatoire).

**Résultats :** 67 patients (56% de femmes) étaient inclus dans l'analyse finale (âge moyen  $59.9 \pm 20.1$  ans). 51 patients présentaient une CM. La présence d'une sclère bleue était significativement associée à la CM pour l'évaluateur 1 ( $p = 0.03$ ) avec une sensibilité de 60.8% [IC95: 46.1;74.2], une spécificité de 68.8% [IC95: 41.3;89%] et une valeur prédictive positive de 86.1% [IC95: 70.5;95.3]. Une tendance non significative ( $p = 0.05$ ) était observée pour les autres évaluateurs. L'analyse informatisée montrait un percentile de bleu plus élevé chez les patients avec CM ( $p = 0.04$ ). L'aire sous la courbe de la courbe ROC était de 0.7 [IC95: 0.54;0.85], donnant une sensibilité de 78.4% [IC95: 63.7;88.7] et une spécificité de 50% [IC95: 24.7;75.3]. L'évaluation clinique et informatisée n'étaient influencées ni par le sexe, la couleur de l'iris ou la présence d'une anémie.

**Conclusion :** la présence d'une sclère bleue a une forte valeur prédictive positive pour le diagnostic de CM. L'analyse informatisée est bien corrélée à l'évaluation clinique. L'amélioration de cette méthode permettrait de proposer un outil intéressant pour le diagnostic de la CM.

Mots clés :

Carence martiale.  
Sclère bleue.  
Diagnostic clinique  
Analyse informatisée

## **Computed and subjective blue scleral color analysis as a diagnostic tool for iron deficiency.**

**Introduction:** Iron deficiency (ID) is common in primary care and its diagnosis requires measurement using ferritin due to its non-specific clinical presentation. Blue sclera is described as a specific and sensitive sign of ID but there are few reports of this in the literature. We aimed to determine the diagnostic value of blue sclera for the diagnosis of ID.

**Methods:** We enrolled a total of 74 patients suspected of having ID in a tertiary medical center. Pictures of their eyes were taken using a smartphone under similar daylight. Three independent physicians who were blinded from iron stores, graded the scleral color in anonymized pictures. A computer analysis of the picture yielded the blue percentile (BP) of the sclera. ID was defined where ferritin  $\leq 30 \mu\text{g/L}$  ( $100 \mu\text{g/L}$  in case of inflammatory syndrome).

**Results:** Final analysis included 67 patients (mean age  $59.9 \pm 20.1$ -year) with a male:female ratio of 0.8. Fifty-one patients had ID. Subjective blue scleral color was associated with ID for physician 1 ( $p = 0.03$ ) with low sensitivity 60.8% [CI95: 46.1;74.2], specificity 68.8% [CI95: 41.3;89%] and high positive predictive value 86.1% [CI95: 70.5;95.3]. A non-significant trend was observed for other physicians ( $p = 0.05$ ). Inter-rater reliability was poor (*Fleiss's*  $\kappa$  0.02-0.23). Computer analysis of the pictures showed higher BP in the ID group ( $p = 0.04$ ). The area-under-the-curve of receiver-operating-characteristics curve was 0.7 [CI95: 0.54;0.85]. Sensitivity was 78.4% [CI95: 63.7;88.7], specificity was 50% [CI95: 24.7;75.3] with a threshold of 29.1. Assessment of blue sclera was not influenced by iris color, sex or anemia.

**Conclusion:** Clinical assessment of blue sclera has good positive-predictive value for ID diagnosis. Computer analysis showed encouraging results correlated to clinical assessment. Improvement of this innovative method could provide simple diagnostic tool for ID diagnosis in primary care.

### Mots clés :

Iron deficiency  
Blue sclera  
Diagnostic tool  
Computer analysis